Leerink Partnrs Analysts Lift Earnings Estimates for Affimed

Affimed (NASDAQ:AFMD) – Research analysts at Leerink Partnrs increased their Q1 2025 earnings per share (EPS) estimates for Affimed in a report released on Tuesday, May 13th. Leerink Partnrs analyst D. Graybosch now forecasts that the biopharmaceutical company will post earnings per share of ($0.39) for the quarter, up from their prior estimate of ($0.59). Leerink Partnrs currently has a “Hold” rating on the stock. The consensus estimate for Affimed’s current full-year earnings is ($4.19) per share. Leerink Partnrs also issued estimates for Affimed’s Q2 2025 earnings at ($0.37) EPS, Q3 2025 earnings at ($0.54) EPS, Q4 2025 earnings at ($0.63) EPS, FY2025 earnings at ($1.93) EPS, FY2026 earnings at ($2.04) EPS, FY2027 earnings at ($1.77) EPS, FY2028 earnings at ($1.43) EPS and FY2029 earnings at ($0.79) EPS.

AFMD has been the subject of several other research reports. Leerink Partners reissued a “market perform” rating and set a $0.39 price objective (down previously from $5.00) on shares of Affimed in a report on Tuesday. HC Wainwright cut shares of Affimed from a “buy” rating to a “neutral” rating in a research note on Wednesday. Wells Fargo & Company reissued an “equal weight” rating and issued a $0.10 price target (down previously from $11.00) on shares of Affimed in a report on Tuesday. Finally, StockNews.com initiated coverage on shares of Affimed in a report on Sunday, May 11th. They set a “sell” rating for the company. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating and two have given a buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $7.90.

Affimed Stock Down 34.5%

Shares of NASDAQ AFMD opened at $0.09 on Thursday. The stock’s 50-day simple moving average is $0.75 and its two-hundred day simple moving average is $1.44. Affimed has a twelve month low of $0.07 and a twelve month high of $8.95. The company has a debt-to-equity ratio of 0.13, a quick ratio of 1.93 and a current ratio of 1.93.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the business. Jane Street Group LLC purchased a new stake in shares of Affimed in the 3rd quarter valued at $44,000. Intellectus Partners LLC raised its position in Affimed by 34.0% in the 4th quarter. Intellectus Partners LLC now owns 126,414 shares of the biopharmaceutical company’s stock worth $150,000 after purchasing an additional 32,053 shares during the period. Finally, Northern Trust Corp bought a new stake in Affimed in the fourth quarter worth $218,000. 30.82% of the stock is owned by hedge funds and other institutional investors.

Affimed Company Profile

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company’s lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development for the treatment acute myeloid.